Researchers at MIT develop new nanoparticles that stimulate the immune system to attack ovarian tumors
Peer-Reviewed Publication
Updates every hour. Last Updated: 5-Nov-2025 21:11 ET (6-Nov-2025 02:11 GMT/UTC)
MIT researchers designed nanoparticles that can deliver an immune-stimulating molecule called IL-12 directly to ovarian tumors. When given to mice along with checkpoint inhibitors, the treatment eliminated metastatic tumors more than 80 percent of the time.
In a review published in Molecular Biomedicine, a team of Chinese scientists summarizes the pivotal role of N⁶-methyladenosine (m⁶A)—the most abundant chemical modification in eukaryotic mRNA—in cancer biology. The authors describe how m⁶A regulators (writers, erasers, and readers) influence tumor progression, metastasis, treatment resistance, and the tumor microenvironment. They also discuss emerging therapeutic strategies, including small-molecule inhibitors, RNA-based editing technologies, and combination therapies, highlighting m⁶A's potential as a diagnostic and prognostic biomarker and a target for precision oncology.
In a comprehensive review published in MedComm - Oncology, a research team sheds new light on the complex biology and therapeutic challenges of breast cancer brain metastasis (BCBrM). The authors detail the multi-step metastatic cascade, from primary tumor invasion to brain colonization, and highlight key signaling pathways such as TGF-β, Wnt/β-catenin, PI3K/AKT, Notch, HER2-HER3, and JAK/STAT. They also explore the dynamic interactions between tumor cells and the brain microenvironment, including astrocytes, microglia, and neurons, which facilitate immune evasion and metabolic adaptation. The review further discusses advances in preclinical models, emerging CNS-penetrant therapies, and innovative clinical trial designs, offering a roadmap for personalized management of BCBrM.
Researchers characterize distinct immune environments in lymphoma, providing a new framework to engage the immune system in treating the disease
Study finds U.S. adults have widespread misperceptions of the cancer risks of alcohol
Scientists discover new target for pain hypersensitivity
Early clinical studies show encouraging results in kidney and prostate cancer
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive form of kidney cancer, leading to the identification of TROP2 as a promising therapeutic target.